3.8 Article

Management of systemic sclerosis: British Society for Rheumatology guideline scope

相关参考文献

注意:仅列出部分参考文献,下载原文获取全部文献信息。
Review Rheumatology

Systemic Sclerosis-Associated Interstitial Lung Disease: How to Incorporate Two Food and Drug Administration-Approved Therapies in Clinical Practice

Dinesh Khanna et al.

Summary: Systemic sclerosis (SSc) has high mortality, with interstitial lung disease (ILD) being a leading cause of death. Nintedanib and tocilizumab are approved by the FDA for SSc-associated ILD treatment. However, the optimal therapeutic strategy is still uncertain, with the review proposing a practical classification based on disease severity and progression risk, discussing different treatment options.

ARTHRITIS & RHEUMATOLOGY (2022)

Review Rheumatology

Consensus-based recommendations for the management of juvenile systemic sclerosis

Ivan Foeldvari et al.

Summary: Juvenile systemic sclerosis (JSSc) is a rare disease in children, and the SHARE initiative provides recommendations for assessment and treatment based on expert opinion and evidence. Focus is on early signs of internal organ involvement, proposing a disease severity score and a stepwise treatment approach to unify care standards in Europe, aiming to reduce morbidity and mortality.

RHEUMATOLOGY (2021)

Review Rheumatology

Update of EULAR recommendations for the treatment of systemic sclerosis

Otylia Kowal-Bielecka et al.

ANNALS OF THE RHEUMATIC DISEASES (2017)

Editorial Material Rheumatology

BSR and BHPR guideline for the treatment of systemic sclerosis

Christopher P. Denton et al.

RHEUMATOLOGY (2016)

Article Medicine, General & Internal

Improved survival in systemic sclerosis is associated with better ascertainment of internal organ disease: a retrospective cohort study

S. I. Nihtyanova et al.

QJM-AN INTERNATIONAL JOURNAL OF MEDICINE (2010)